Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LIVN vs ITGR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LIVN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–4 Matrix Metrics)

LIVN Overall Winner 6-Pillar Tally: LIVN 6 – 0 ITGR Matrix Metrics: LIVN 6 – 4 ITGR

As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over Integer Holdings Corporation (ITGR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LIVN carries a Unified Composite Score of 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin), whereas ITGR carries 65.5/100 (BUY) at $126.97 (18.5x Forward P/E, 9.8% operating margin).

  • Composite vs. Pillar Nuance: While ITGR currently prints a higher short-term Unified Composite Score (65.5/100 BUY vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 9.8% operating margin) and revenue trajectory (+9.9% vs. -3.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LIVN vs ITGR
LIVN NASDAQ Head-to-Head Winner
LivaNova PLC Ordinary Shares
Electromedical & Electrotherapeutic Apparatus
$92.07
-2.61% 1D
Market Cap $5.1B
TTM Revenue $1.51B
Forward P/E 19.5x
Beta / 30D Vol 0.98β · 67% Vol
Unified Composite Score
38.5 / 100 SELL
Tech 23.0 Fund 40.0 Flow 70.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $87.27 · SMA50: $81.35
ITGR NYSE
Integer Holdings Corporation
Electromedical & Electrotherapeutic Apparatus
$126.97
+0.21% 1D
Market Cap $4.3B
TTM Revenue $1.83B
Forward P/E 18.5x
Beta / 30D Vol 0.53β · 2% Vol
Unified Composite Score
65.5 / 100 BUY
Tech 59.0 Fund 59.0 Flow 60.0 Mom 58.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 63
RSI-14: 63.2 · SMA20: $126.62 · SMA50: $126.47

6-Pillar Scorecard Institutional Category Breakdown (LIVN 6 – 0 ITGR)

Columns: Metric · LIVN · ITGR
1. Valuation Multiples LIVN
Forward P/E 19.5x 18.5x
Trailing P/E 26.5x 42.5x
PEG Ratio 0.93x 3.06x
EV / Revenue 3.2x 3.1x
2. Growth & Scale LIVN
Revenue Growth (YoY) +9.9% -3.9%
Earnings Growth (YoY) -78.2% -61.3%
TTM Revenue (USD) $1.51B $1.83B
Market Cap $5.1B $4.3B
3. Profitability & Quality LIVN
Gross Margin 67.6% 25.1%
Operating Margin 14.3% 9.8%
Net Profit Margin 13.0% 5.7%
Return on Equity (ROE) 15.5% 6.0%
4. Balance Sheet & Cash Flow LIVN
Cash Generation (TTM) $129M $83M
Cash Flow Margin 8.6% 4.5%
Net Cash / Leverage $206M Net Cash $1.33B Net Debt (0.78x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LIVN
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 36.9% (11th %ile) 0.7% (<1st %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat LIVN
OpEx & R&D Intensity 53.3% of Rev ($803M) 15.3% of Rev ($279M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LIVN (6) vs ITGR (4)
Institutional Metric LIVN ITGR Criterion Row Edge
Market Capitalization
Scale
$5.1B $4.3B Larger Scale LIVN
Trailing P/E Ratio
Valuation
26.5x 42.5x Lower Multiple LIVN
Forward P/E Ratio
Valuation
19.5x 18.5x Lower Multiple ITGR
Revenue Growth (YoY)
Growth
+9.9% -3.9% Higher Growth LIVN
Operating Margin (TTM)
Profitability
14.3% 9.8% Higher Margin LIVN
Net Profit Margin
Profitability
13.0% 5.7% Higher Margin LIVN
Return on Equity (ROE)
Capital Efficiency
15.5% 6.0% Higher ROE LIVN
52-Week Range Position
Momentum
84% ($52–$99) 91% ($67–$133) Stronger Trend ITGR
Beta / 30D Volatility
Risk Regime
0.98β · 67% Vol 0.53β · 2% Vol Lower Realized Risk ITGR
Unified Institutional Score
Composite Signal
38.5 / 100 (SELL) 65.5 / 100 (BUY) Higher Composite ITGR
Trailing 12M Revenue (USD)
Operating Scale
$1.51B $1.83B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.6% 25.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 3.2x EV/Rev 3.06x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$129M ($206M Net Cash) $83M ($1.33B Net Debt (0.78x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LIVN +18.94 pp
LIVN: +19.15% · ITGR: +0.21%
3M Horizon LIVN +14.25 pp
LIVN: +15.75% · ITGR: +1.5%
6M Horizon ITGR +13.14 pp
LIVN: +27.98% · ITGR: +41.12%
1Y Horizon ITGR +15.88 pp
LIVN: +71.53% · ITGR: +87.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LIVN Revenue ITGR Revenue LIVN Op. Margin ITGR Op. Margin Margin Leader
FY2018 $1.11B $1.22B -22.4% 12.8% ITGR
FY2019 $1.08B $1.26B -15.8% 12.5% ITGR
FY2020 $930M $1.07B -29.3% 11.2% ITGR
FY2021 $1.04B $1.22B -0.1% 11.1% ITGR
FY2022 $1.02B $1.33B -7.5% 8.5% ITGR
FY2023 $1.15B $1.56B -5.9% 10.5% ITGR
FY2024 $1.25B $1.72B 10.3% 12.1% ITGR
FY2025 $1.39B $1.85B 14.4% 11.9% LIVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LIVN CONSOLIDATION
97d in phase · OBV NEUTRAL
Current IV 36.9%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LIVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ITGR CONSOLIDATION
71d in phase · OBV NEUTRAL
Current IV 0.7%
IV Percentile <1st %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ITGR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LIVN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $5.1B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 53.3% of Rev ($803M)
90D Engineering Disclosures 0 Published
ITGR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $4.3B market capitalization and 9.8% operating margin.
OpEx & R&D Reinvestment 15.3% of Rev ($279M)
90D Engineering Disclosures 0 Published

Investor FAQ LIVN vs ITGR Key Questions & Quantitative Answers

As of Nov 19, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over Integer Holdings Corporation (ITGR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LIVN carries a Unified Composite Score of 38.5/100 (SELL) at $92.07 (19.5x Forward P/E, 14.3% operating margin), whereas ITGR carries 65.5/100 (BUY) at $126.97 (18.5x Forward P/E, 9.8% operating margin). Composite vs. Pillar Nuance: While ITGR currently prints a higher short-term Unified Composite Score (65.5/100 BUY vs. LIVN 38.5/100 SELL), LIVN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 9.8% operating margin) and revenue trajectory (+9.9% vs. -3.9% YoY).

LIVN leads the Growth & Scale pillar: LIVN posts +9.9% YoY revenue growth and -78.2% YoY earnings growth on $1.51B TTM revenue (67.6% gross margin, 14.3% operating margin), compared with ITGR at -3.9% YoY revenue growth and -61.3% YoY earnings growth on $1.83B TTM revenue (25.1% gross margin, 9.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LIVN cumulative revenue shifted +25.2% while ITGR shifted +51.6%. In operating R&D and SG&A reinvestment, LIVN deploys 53.3% of Rev ($803M) (0 90-day corporate R&D disclosures) versus 15.3% of Rev ($279M) (0 disclosures) for ITGR.

LIVN screens cheaper on headline valuation multiples. LIVN trades at 19.5x Forward P/E, 26.5x Trailing P/E, 0.93x PEG, and 3.2x EV/Revenue (8.6% FCF margin), whereas ITGR trades at 18.5x Forward P/E, 42.5x Trailing P/E, 3.06x PEG, and 3.1x EV/Revenue (4.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LIVN (15.5% ROE) versus ITGR (6.0% ROE) capital efficiency.

In options market volatility and institutional positioning, LIVN carries 36.9% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.98β · 67% Vol realized risk). By comparison, ITGR carries 0.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.53β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.